ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BIM), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Grothey, A. [1 ]
Yaeger, R. [2 ]
Paez, D. [3 ]
Tabernero, J. [4 ]
Taieb, J. [5 ]
Yoshino, T. [6 ]
Groc, M. [7 ]
Vedovato, J. [7 ]
Chetaille, E. [7 ]
Van Cutsem, E. [7 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Georges Pompidou European Hosp, Paris, France
[6] Natl Canc Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[7] UZ Leuven, Campus Gasthuisberg, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 400
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [1] ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Grothey, A.
    Tabernero, J.
    Taieb, J.
    Yaeger, R.
    Yoshino, T.
    Maiello, E.
    Fernandez, E. Elez
    Casado, A. Ruiz
    Ross, P.
    Andre, T.
    Kato, T.
    Ruffinelli, J.
    Graham, J.
    Van den Eynde, M.
    Vera, R.
    Jean, B.
    Roussel, E. Carriere
    Cahuzac, C.
    Issiakhem, Z.
    Vedovato, J.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S242 - S243
  • [2] ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Van Cutsem, E.
    Taieb, J.
    Yaeger, R.
    Yoshino, T.
    Maiello, E.
    Elez, E.
    Dekervel, J.
    Ross, P.
    Ruiz Casado, A.
    Graham, J.
    Kato, T.
    Ruffinelli, J.
    Andre, T.
    Roussel, E. Carriere
    Klauck, I.
    Groc, M.
    Grothey, A.
    Vedovato, J.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S222 - S222
  • [3] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Desai, Jayesh
    Kopetz, Scott
    Aderka, Dan
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Ciardiello, Fortunato
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Price, Timothy
    Karapetis, Chris
    Murphy, Felicity
    Gollerkeri, Ashwin
    Golden, Adele
    Edwards, Michelle L.
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 119 - 120
  • [4] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Aderka, Dan
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Gollerkeri, Ashwin
    Golden, Adele
    Edwards, Michelle L.
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
    Vogel, Arndt
    Hegewisch-Becker, Susanna
    Prager, Gerald
    Folprecht, Gunnar
    Stahl, Michael
    Kopetz, Scott
    Grothey, Axel
    van Cutsetn, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Loupakis, Fotios
    Hong, Y.
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia-Alfons, Pilar
    Sandor, Victor
    Christy-Bittel, Farina
    Anderson, Lisa
    Tabernero, Josep
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
  • [6] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Desai, Jayesh
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia Alfonso, Pilar
    Price, Timothy
    Strickland, Andrew
    Tebbutt, Niall
    Karapetis, Christos
    Chantrill, Lorraine
    Murphy, Felicity
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
  • [7] Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Cuyle, Pieter-Jan A. R.
    Huijberts, Sanne
    Schellens, Jan H. M.
    Elez, Elena
    Fakih, Marwan
    Viladot, Clara Montagut
    Peeters, Marc
    Desai, Jayesh
    Yoshino, Takayuki
    Ciardiello, Fortunato
    Wasan, Harpreet Singh
    Maharry, Kati
    Christy-Bittel, Janna
    Gollerkeri, Ashwin
    Van Cutsem, Eric
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Taieb, Julien
    Yaeger, Rona
    Yoshino, Takayuki
    Grothey, Axel
    Maiello, Evaristo
    Elez, Elena
    Dekervel, Jeroen
    Ross, Paul
    Ruiz-Casado, Ana
    Graham, Janet
    Kato, Takeshi
    Ruffinelli, Jose C.
    Andre, Thierry
    Roussel, Edith Carriere
    Klauck, Isabelle
    Groc, Melanie
    Vedovato, Jean-Claude
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2628 - +
  • [9] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
    Aderka, D.
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Golden, A.
    Edwards, M.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214
  • [10] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    [J]. DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
12345